These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 6298890)

  • 1. U-50,488, a selective kappa opioid agonist: comparison to other reputed kappa agonists.
    Von Voigtlander PF; Lewis RA
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):467-70. PubMed ID: 6298890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. U-50,488: a selective and structurally novel non-Mu (kappa) opioid agonist.
    Vonvoigtlander PF; Lahti RA; Ludens JH
    J Pharmacol Exp Ther; 1983 Jan; 224(1):7-12. PubMed ID: 6129321
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discriminative stimulus properties of U50,488 and morphine: effects of training dose on stimulus substitution patterns produced by mu and kappa opioid agonists.
    Picker MJ; Doty P; Negus SS; Mattox SR; Dykstra LA
    J Pharmacol Exp Ther; 1990 Jul; 254(1):13-22. PubMed ID: 2164087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential cross-tolerance to mu and kappa opioid agonists in morphine-tolerant rats responding under a schedule of food presentation.
    Picker MJ; Negus SS; Powell KR
    Psychopharmacology (Berl); 1991; 103(1):129-35. PubMed ID: 1848712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. I. Effects of opioid kappa receptor agonists bremazocine and U-50,488 on secretion of PRL and GH: comparison with morphine.
    Krulich L; Koenig JI; Conway S; McCann SM; Mayfield MA
    Neuroendocrinology; 1986; 42(1):75-81. PubMed ID: 3001565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Agonist and antagonist activity of kappa opioids in the squirrel monkey: I. Antinociception and urine output.
    Craft RM; Dykstra LA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):327-33. PubMed ID: 1309876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hyperalgesic effect of the selective kappa opioid agonist, U-50488H in mice.
    Ramabadran K
    Jpn J Pharmacol; 1983 Dec; 33(6):1289-92. PubMed ID: 6321836
    [No Abstract]   [Full Text] [Related]  

  • 8. Discriminative stimulus effects of mu and kappa opioids in the pigeon: analysis of the effects of full and partial mu and kappa agonists.
    Picker MJ; Dykstra LA
    J Pharmacol Exp Ther; 1989 May; 249(2):557-66. PubMed ID: 2566680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Further study of kappa opioids on increased urination.
    Leander JD
    J Pharmacol Exp Ther; 1983 Oct; 227(1):35-41. PubMed ID: 6137557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of mu and kappa opioid receptor agonists on rat plasma corticosterone levels.
    Hayes AG; Stewart BR
    Eur J Pharmacol; 1985 Oct; 116(1-2):75-9. PubMed ID: 2996912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of mu- and kappa-opioid agonists on the electroconvulsive seizure threshold in mice and antagonism by naloxone and MR 2266.
    Frey HH
    Pharmacol Toxicol; 1988 Mar; 62(3):150-4. PubMed ID: 2836842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agonist and antagonist activity of kappa opioids in the squirrel monkey: II. Effect of chronic morphine treatment.
    Craft RM; Dykstra LA
    J Pharmacol Exp Ther; 1992 Jan; 260(1):334-42. PubMed ID: 1309877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid kappa receptors and the secretion of prolactin (PRL) and growth hormone (GH) in the rat. II. GH and PRL release-inhibiting effects of the opioid kappa receptor agonists bremazocine and U-50,488.
    Krulich L; Koenig JI; Conway S; McCann SM; Mayfield MA
    Neuroendocrinology; 1986; 42(1):82-7. PubMed ID: 3001566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential cross-tolerance to opioid agonists in morphine-tolerant pigeons responding under a schedule of food presentation.
    Craft RM; Picker MJ; Dykstra LA
    J Pharmacol Exp Ther; 1989 May; 249(2):386-93. PubMed ID: 2542528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose- and time-dependent bimodal effects of kappa-opioid agonists on locomotor activity in mice.
    Kuzmin A; Sandin J; Terenius L; Ogren SO
    J Pharmacol Exp Ther; 2000 Dec; 295(3):1031-42. PubMed ID: 11082438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological actions of a novel mixed opiate agonist/antagonist: naloxone benzoylhydrazone.
    Gistrak MA; Paul D; Hahn EF; Pasternak GW
    J Pharmacol Exp Ther; 1989 Nov; 251(2):469-76. PubMed ID: 2553921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kappa opioid agonists and antagonists: effects on drinking and urinary output.
    Leander JD
    Appetite; 1984 Mar; 5(1):7-14. PubMed ID: 6091543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A selective kappa-opioid agonist, U-50,488H, blocks the development of tolerance to morphine analgesia in rats.
    Yamamoto T; Ohno M; Ueki S
    Eur J Pharmacol; 1988 Oct; 156(1):173-6. PubMed ID: 2850208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions between mu and kappa opioid agonists in the rat drug discrimination procedure.
    Negus SS; Picker MJ; Dykstra LA
    Psychopharmacology (Berl); 1990; 102(4):465-73. PubMed ID: 1965748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of sham and full spinalization on the systemic potency of mu- and kappa-opioids on spinal nociceptive reflexes in rats.
    Herrero JF; Headley PM
    Br J Pharmacol; 1991 Sep; 104(1):166-70. PubMed ID: 1664760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.